Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna

Regulatory

STOCKHOLM, 26 May, 2021 — CEO Jonas Ekblom presents Promore Pharma AB at a digital event for small- and mid-sized companies, organized by Aktiespararna, on 9 June at 13.30.

Jonas Ekblom, CEO of Promore Pharma, presents the company's revised strategy with a focus on skin scar prevention and pharmaceutical product development, as well as the new share issue that the company plans to carry out on 3-17 June, 2021. The presentation will be held in Swedish.

Participants have the opportunity to ask questions in connection with the presentation by sending text messages to +46 79 347 98 45 or by emailing event@aktiespararna.se. The questions will be conveyed by Aktiespararna's moderator in connection with the general discussion after the presentation. Questions can be submitted now, or in connection with the presentation.

The presentation can be followed live at aktiespararna.se/tv/live. The event is open to everyone and does not require membership in Aktiespararna. No registration is required to follow the event digitally.

The following day, all presentations will be posted on aktiespararna.se/tv/evenemang.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Attachments

Promore Pharma participates in “Småbolagsdagarna 2021”, an event organized by Aktiespararna

Documents